Key Market Indicators
Estonia's insulin import market is projected to shrink significantly in the coming years. By 2028, imports are expected to fall to around $380,000 from approximately $2.07 million in 2023, marking an average annual decline of 26%. This downward trend continues a pattern observed since 2000, with demand decreasing by an average of 11% each year. In contrast, Estonia’s insulin export market is set for modest growth. Exports are forecast to reach about $59,000 by 2028, up from $51,000 in 2023, reflecting an average annual growth rate of 2.2%. Since 2001, the country's insulin supply has expanded considerably, with an average yearly increase of 30%. In 2023, Estonia ranked 33rd in global insulin exports, with Japan surpassing it at the same $51,000 level. Leading the global rankings were France, Italy, and China, occupying the second, third, and fourth positions, respectively.
